All News

RheumNow Podcast square

ICYMI: RheumNow Podcast – Tofacitinib Safety Concerns

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
2020 Year Review

ICYMI: 2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Lungs ILD

ICYMI: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
patient.safety.jpg

ICYMI: JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
RheumNow Podcast square

RheumNow Podcast – As Good As I Ever Was (7.2.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jack Cush, MD

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast - Best of EULAR 2021

Jack Cush, MD

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article
Lungs ILD

RA ILD: Stepping out of the shadows

Richard Conway, MBBChBAO, PhD

Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at EULAR 2021. Here are four selected for review.

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stablized their FVC, DLCO, CHest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/1dGufcKsha

Links:

Dr. John Cush RheumNow ( View Tweet)

Serious problem! Pulmonologists believe that MTX causes and/or worsens ILD. MTX causes hypersensitivity pneumonitis, not ILD. RA, lupus DM, PSS cause ILD and they may need MTX to manage their disease. Do your own research, look at this paper to start. https://t.co/vUyCxJP2Mh

Links:

Dr. John Cush RheumNow ( View Tweet)

Stroke risk is increased in arthritis (RR 1.36, 95% CI: 1.27–1.46); esp for RA (RR 1.38), AS (RR 1.49), PsA (1.33) & gout (1.40); but NOT osteoarthritis (RR=1.03). Apparently Inflammation drives this risk. https://t.co/Snb6OrtZJH

Links:

Dr. John Cush RheumNow ( View Tweet)

RA ILD: Stepping out of the shadows Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis (RA) with up to 8% of patients affected with clinically significant ILD. https://t.co/BaoqQLKR5C https://t.co/duIqHVfCAa

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept in RA ILD Dr. Conway ( @RichardPAConway) discusses abstract POS0595 at the virtual #EULAR2021 meeting. https://t.co/rpVuHOkS5w https://t.co/7pNzh6sb7a

Links:

Dr. John Cush RheumNow ( View Tweet)
Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew ) Dr. David Liew reviews abstract OP0124 presented at #EULAR2021 https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw

Links:

Dr. John Cush RheumNow ( View Tweet)
Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC
Richard Conway RichardPAConway ( View Tweet)
Just a reminder: RA-ILD doesn't just happen in early disease; risk continues on long after diagnosis. PS don't smoke if you have RA; smokers have an adj HR 1.92 PPS don't smoke if you don't want to get RA PPPS don't smoke. @MayoClinic POS0210 #EULAR2021 @RheumNow https://t.co/elhvJrK7B4
David Liew drdavidliew ( View Tweet)
Lots of discussion about RA-ILD, but what about bronchiectasis (BR) in RA? We found a pooled prevalence of RA-BR of 18.7% (some may have been subclinical). POS0522 Prevalence of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis #EULAR2021 @Janetbirdope

Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)

Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

#EULAR2021 OP0290: Cluster analysis of APLS 4 Clusters: ⭐️ 2ndary APS, non-criteria ⭐️ ♂️ with CV risks ⭐️OB morbidity ⭐️Isolated LA + @RheumNow

Eric Dein ejdein1 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×